Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial

K Seidensaal, M Kieser, A Hommertgen, C Jaekel, S B Harrabi, K Herfarth, G Mechtesheimer, B Lehner, M Schneider, H Nienhueser, S Fröhling, G Egerer, J Debus, M Uhl, K Seidensaal, M Kieser, A Hommertgen, C Jaekel, S B Harrabi, K Herfarth, G Mechtesheimer, B Lehner, M Schneider, H Nienhueser, S Fröhling, G Egerer, J Debus, M Uhl

Abstract

Background: Following surgery for soft tissue sarcoma of the retroperitoneum, the predominant pattern of failure is local recurrence, which remains the main cause of death. Radiotherapy is utilized to reduce recurrence rates but the efficacy of this strategy has not been definitely established. As treatment tolerability is more favorable with preoperative radiotherapy, normofractionated neoadjuvant treatment is the current approach. The final results of the prospective, randomized STRASS (EORTC 62092) trial, which compared the efficacy of this combined treatment to that of surgery alone, are still awaited; preliminary results presented at the 2019 ASCO Annual Meeting indicated that combined treatment is associated with better local control in patients with liposarcoma (74.5% of the cohort, 11% benefit in abdominal progression free survival after 3 years, p = 0.049). Particles allow better sparing of surrounding tissues at risk, e.g., bowel epithelium, and carbon ions additionally offer biologic advantages and are preferred in slow growing tumors. Furthermore, hypofractionation allows for a significantly shorter treatment interval with a lower risk of progression during radiotherapy.

Methods and design: We present a prospective, randomized, monocentric phase II trial. Patients with resectable or marginally resectable, histologically confirmed soft tissue sarcoma of the retroperitoneum will be randomized between neoadjuvant proton or neoadjuvant carbon ion radiotherapy in active scanning beam application technique (39 Gy [relative biological effectiveness, RBE] in 13 fractions [5-6 fractions per week] in each arm). The primary objective is the safety and feasibility based on the proportion of grade 3-5 toxicity (CTCAE, version 5.0) in the first 12 months after surgery or discontinuation of treatment for any reason related to the treatment. Local control, local progression-free survival, disease-free survival, overall survival, and quality of life are the secondary endpoints of the study.

Discussion: The aim of this study is to confirm that hypofractionated, accelerated preoperative radiotherapy is safe and feasible. The rationale for the use of particle therapy is the potential for reduced toxicity. The data will lay the groundwork for a randomized phase III trial comparing hypofractionated proton and carbon ion irradiation with regard to local control.

Trial registration: ClinicalTrials.gov NCT04219202 . Retrospectively registered on January 6, 2020.

Keywords: Carbon ion therapy; Heavy ion therapy; Hypofractionation; Irradiation; Proton therapy; Randomized trial; Retroperitoneal soft tissue sarcoma.

Conflict of interest statement

The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Fig. 1
Fig. 1
MRT and dose distribution of the carbon ion plan of a 33-year-old patient with first diagnosed retroperitoneal liposarcoma

References

    1. Nussbaum DP, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol. 2016;17(7):966–975. doi: 10.1016/S1470-2045(16)30050-X.
    1. Jemal A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30. doi: 10.3322/canjclin.55.1.10.
    1. Tan MCB, et al. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. Ann Surg. 2016;263(3):593–600. doi: 10.1097/SLA.0000000000001149.
    1. Lewis JJ, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–365. doi: 10.1097/00000658-199809000-00008.
    1. Cody Iii HS, et al. The continuing challenge of retroperitoneal sarcomas. Cancer. 1981;47(9):2147–2152. doi: 10.1002/1097-0142(19810501)47:9<2147::AID-CNCR2820470907>;2-Z.
    1. Singer S, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358–370. doi: 10.1097/01.sla.0000086542.11899.38.
    1. Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610–1616. doi: 10.1002/cncr.21761.
    1. Uhl M, Herfarth K, Debus J. Comparing the use of protons and carbon ions for treatment. Cancer J. 2014;20(6):433–439. doi: 10.1097/PPO.0000000000000078.
    1. Weber U, Kraft G. Comparison of carbon ions versus protons. Cancer J. 2009;15(4):325–332. doi: 10.1097/PPO.0b013e3181b01935.
    1. DeLaney TF, et al. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. 2017;2(1):85–93. doi: 10.1016/j.adro.2016.12.003.
    1. Haberer T, et al. Magnetic scanning system for heavy ion therapy. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 1993;330(1):296–305. doi: 10.1016/0168-9002(93)91335-K.
    1. Combs SE, et al. Heidelberg ion therapy center (HIT): initial clinical experience in the first 80 patients. Acta Oncol. 2010;49(7):1132–1140. doi: 10.3109/0284186X.2010.498432.
    1. Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat. 1998;52(2):119–126.
    1. van Buuren S. Flexible imputation of missing data. 2012.
    1. Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clin Trials. 2008;5(3):225–239. doi: 10.1177/1740774508091600.
    1. Bonvalot S, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27(1):31–37. doi: 10.1200/JCO.2008.18.0802.
    1. Le Péchoux C, et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann Oncol. 2013;24(3):832–837. doi: 10.1093/annonc/mds516.
    1. Kelly KJ, et al. Comparison of perioperative radiation therapy and surgery versus surgery alone in 204 patients with primary retroperitoneal sarcoma: a retrospective 2-institution study. Ann Surg. 2015;262(1):156–162. doi: 10.1097/SLA.0000000000001063.
    1. Gronchi A, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27(1):24–30. doi: 10.1200/JCO.2008.17.8871.
    1. Gronchi A, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012;23(4):1067–1073. doi: 10.1093/annonc/mdr323.
    1. Roeder F, et al. Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis. BMC Cancer. 2014;14:617. doi: 10.1186/1471-2407-14-617.
    1. Guerrero Urbano T, et al. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol) 2010;22(3):236–244. doi: 10.1016/j.clon.2010.01.005.
    1. Chopra S, et al. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study. Int J Radiat Oncol Biol Phys. 2014;88(3):630–635. doi: 10.1016/j.ijrobp.2013.11.214.
    1. Swanson EL, et al. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. Int J Radiat Oncol Biol Phys. 2012;83(5):1549–1557. doi: 10.1016/j.ijrobp.2011.10.014.
    1. Koseła-Paterczyk H, et al. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014;40(12):1641–1647. doi: 10.1016/j.ejso.2014.05.016.
    1. Pennington JD, et al. Long-term outcomes with ifosfamide-based hypofractionated preoperative chemoradiotherapy for extremity soft tissue sarcomas. Am J Clin Oncol. 2018;41(12):1154–1161. doi: 10.1097/COC.0000000000000443.
    1. van Leeuwen CM, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13(1):96. doi: 10.1186/s13014-018-1040-z.
    1. Serizawa I, et al. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Physics. 2009;75(4):1105–1110. doi: 10.1016/j.ijrobp.2008.12.019.
    1. Bonvalot S, et al. STRASS (EORTC 62092): a phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. J Clin Oncol. 2019;37(15_suppl):11001. doi: 10.1200/JCO.2019.37.15_suppl.11001.
    1. Bonvalot S, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–1377. doi: 10.1016/S1470-2045(20)30446-0.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit